Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $929,124.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total transaction of $929,124.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $33,551.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Stock Up 1.7 %

Shares of NASDAQ UTHR opened at $262.40 on Monday. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $262.51. The firm has a fifty day moving average of $236.86 and a 200-day moving average of $229.35. The stock has a market capitalization of $11.64 billion, a PE ratio of 12.41 and a beta of 0.54. The company has a quick ratio of 4.28, a current ratio of 3.77 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. During the same period in the previous year, the company earned $4.86 EPS. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Co. will post 23.88 EPS for the current year.

Institutional Trading of United Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new stake in United Therapeutics during the 4th quarter worth $100,519,000. Nordea Investment Management AB boosted its position in United Therapeutics by 677.6% during the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after purchasing an additional 262,222 shares during the period. Avidity Partners Management LP purchased a new stake in United Therapeutics during the 4th quarter worth $52,158,000. Comerica Bank boosted its position in United Therapeutics by 2,697.2% during the 3rd quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock worth $35,368,000 after purchasing an additional 150,989 shares during the period. Finally, Victory Capital Management Inc. boosted its position in United Therapeutics by 309.7% during the 4th quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock worth $29,501,000 after purchasing an additional 101,419 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the subject of a number of research reports. SVB Leerink initiated coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target for the company. Oppenheimer lifted their price objective on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday. The Goldman Sachs Group lifted their price objective on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday. Wells Fargo & Company lifted their price objective on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, March 7th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $308.78.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.